Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.

Oncotarget - 7 Feb 2017

Bonuccelli Gloria, Peiris-Pages Maria, Ozsvari Bela, Martinez-Outschoorn Ubaldo E, Sotgia Federica, Lisanti Michael P

Abstract excerpt

In this report, we systematically examined the role of telomerase activity in lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung (A549) and ovarian (SKOV3) cancer cells, transduced with the hTERT-GFP reporter, we then employed GFP-expression levels to fractionate these cell lines into GFP-high and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to Neoplastic Stem Cells

Share to Piperazines

Share to Pyridines

Share to Telomerase

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28039467
DOI: 10.18632/oncotarget.14196
PMCID: PMC5354777

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.PMID 28039467Read ↗

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial EnergySemantic proximity Read ↗

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cellsSemantic proximity Read ↗

Hallmarks of cancer stem cell metabolismSemantic proximity Read ↗

Cancer Stem Cell Metabolism and Potential Therapeutic TargetsSemantic proximity Read ↗

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistantSemantic proximity Read ↗

Targeting cancer stem cells from a metabolic perspectiveSemantic proximity Read ↗

Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype.Semantic proximity Read ↗

A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem CellsSemantic proximity Read ↗

Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cellsSemantic proximity Read ↗

SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production.Semantic proximity Read ↗

The metabolic landscape of cancer stem cellsSemantic proximity Read ↗

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like PhenotypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.